drugset
Drugs / PGT121
last change Feb 2026 re-read 9 days ago

PGT121

Monoclonal antibody

Developed for
HIV infectious disease · AIDS · acquired immunodeficiency
Investigated by
Beth Israel Deaconess Medical Center · International AIDS Vaccine Initiative · National Institute of Allergy and Infectious Diseases (NIAID) · Boris Juelg, MD PhD · Harvard School of Public Health (HSPH) · Janssen Pharmaceuticals
+8 more · Mills Clinical Research, Los Angeles CA · Orlando Immunology Clinic · Orlando Immunology Clinic, Orlando FL · Ragon Institute of MGH, MIT and Harvard · Ragon Institute of MGH, MIT and Harvard, Boston MA · University of Minnesota · University of Texas Health, Houston AIDS Research Team (HART) · University of Texas Health, Houston AIDS Research Team (HART), Houston TX

Trials 5

today NCT04983030 · Ph 1/2 NCT04144335 · Ph 1/2 NCT03928821 · Ph 1 NCT03205917 · Ph 1 NCT02960581 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials · 2 met primary
Phase 1 NCT03928821 Jul 2019 → Mar 2021 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT03205917 Oct 2017 → Apr 2020 HIV infectious disease International AIDS Vaccine Initiative Completed Met primary
Phase 1 NCT02960581 Nov 2016 → Jul 2019 HIV infectious disease International AIDS Vaccine Initiative Completed Met primary
Phase 1/22 trials
Phase 1/2 NCT04983030 Apr 2022 → Feb 2026 AIDS, acquired immunodeficiency Boris Juelg, MD PhD Completed No outcome recorded
Phase 1/2 NCT04144335 Jan → Dec 2020 AIDS University of Minnesota Withdrawn No outcome recorded
Comparator or background therapy1 trial
Phase 1/2 NCT03721510 Comparator Dec 2018 → Oct 2021 HIV infectious disease International AIDS Vaccine Initiative Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2018-03-04 Gilead Sciences Results Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys gilead.com ↗
Data from the study conducted in simian-human immunodeficiency virus (SHIV)-infected rhesus monkeys on suppressive antiretroviral therapy (ART) demonstrated that a combination treatment of GS-9620 and PGT121 resulted in a subset of animals maintaining viral suppression after ART discontinuation.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as PGT121 “the Broadly Neutralizing Antibodies VRC07-523LS and PGT121 Plus or Minus haNK Cells for Reduction of HIV Reservoirs” NCT04144335 ↗
5

NCT03205917 ↗

NCT04983030 ↗

NCT03928821 ↗

NCT02960581 ↗

NCT03721510 ↗
Action Inhibit “PGT121 mAb was chosen for this study because it is potent, neutralizes a wide array of HIV viruses” NCT02960581 ↗
Modality Monoclonal antibody “PGT121 monoclonal antibody” NCT02960581 ↗
Route Intravenous “3mg/kg administered by IV Infusion” NCT02960581 ↗